Legend Biotech’s CARVYKTI® Shows Promising Results

Legend Biotech (LEGN) has released an update.

Legend Biotech has announced promising results from their Phase 2 and Phase 3 studies of CARVYKTI® in treating multiple myeloma, showing significant improvements in patient outcomes, including deep and durable responses and improved progression-free survival compared to standard therapies. The data, which were presented at key medical conferences, underpin the FDA’s recent approval of CARVYKTI® for use after just one prior line of therapy. Despite strong efficacy, the treatment has also shown a consistent safety profile, with serious adverse events such as cytokine release syndrome and neurologic toxicities.

For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.